Instrument Inactif

Autres langues Neos Therapeutics, Inc.

Actions

NEOS

US64052L1061

Produits pharmaceutiques

Autres langues

23/06/25	Aytu Biopharma, Inc. Announces Amendment No. 6 to Loan and Security Agreement with Eclipse Lender
31/01/22	Aytu Biopharma, Inc. Enters into Loan and Security Agreement, by and Among Neos Therapeutics, Inc., Neos Therapeutics Brands, Llc, Neos Therapeutics, Lp, Neos Therapeutics Commercial, Llc, Pharmafab Texas, Llc, Aytu Therapeutics, Llc, Innovus Pharmaceuticals, Inc., Semprae Laboratories, Inc., Novalere, Inc., Supplement Hunt, Inc., and Delta Prime Savings Club, Inc. as Borrowers
22/03/21	Aytu BioScience : Completes Merger With Neos Therapeutics
22/03/21	NEOS THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements (form 8-K)
22/03/21	Neos Therapeutics, Inc. Announces Board Changes
22/03/21	Neos Therapeutics, Inc. Announces Cessation of Richard Eisenstadt as Chief Financial Officer
22/03/21	Neos Therapeutics, Inc. Announces Cessation of Gerald Mclaughlin as Chief Executive Officer
22/03/21	Neos Therapeutics, Inc.(NasdaqGM:NEOS) dropped from S&P TMI Index
22/03/21	Neos Therapeutics : Aytu BioScience Announces Close of Merger with Neos Therapeutics
19/03/21	Neos Therapeutics, Inc.(NasdaqGM:NEOS) dropped from NASDAQ Composite Index
19/03/21	Aytu BioScience, Inc. completed the acquisition of Neos Therapeutics, Inc..
12/03/21	Neos Therapeutics : Merger With Aytu BioScience Endorsed by Proxy Advisers Glass, Lewis
12/03/21	Glass Lewis, a Leading Independent Proxy Advisory Firm, Recommends Neos Therapeutics Stockholders Vote “FOR” the Pending Merger With Aytu BioScience
10/03/21	Leading Independent Proxy Advisory Firm ISS Recommends Neos Therapeutics Stockholders Vote “FOR” the Pending Merger With Aytu BioScience
10/02/21	Aytu BioScience : Neos Therapeutics Shareholders To Vote on Deal In March
10/02/21	Aytu BioScience and Neos Therapeutics Announce Special Meetings of Stockholders Related to Proposed Merger to Be Held on March 18, 2021
08/02/21	NEOS THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)
08/02/21	Neos Therapeutics, Inc. announced that it has received $5 million in funding from Aytu BioScience, Inc.
11/01/21	NEOS THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
04/01/21	Neos Therapeutics to Present at H.C. Wainwright Virtual BioConnect Conference
30/12/20	NEOS THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits (form 8-K)
11/12/20	NEOS THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
10/12/20	DJ Industrial : Wall Street Slips Pre-Bell as Stimulus Impasse Drags, Jobless Claims Surge
10/12/20	Neos Therapeutics : Aytu BioScience and Neos Therapeutics Enter Definitive Merger Deal
10/12/20	NEOS THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)